JP2022512672A5 - - Google Patents
Info
- Publication number
- JP2022512672A5 JP2022512672A5 JP2021519849A JP2021519849A JP2022512672A5 JP 2022512672 A5 JP2022512672 A5 JP 2022512672A5 JP 2021519849 A JP2021519849 A JP 2021519849A JP 2021519849 A JP2021519849 A JP 2021519849A JP 2022512672 A5 JP2022512672 A5 JP 2022512672A5
- Authority
- JP
- Japan
- Prior art keywords
- binding protein
- antibody
- use according
- fused
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18199879.0A EP3636284A1 (en) | 2018-10-11 | 2018-10-11 | Binding protein-toxin conjugates comprising anthracyclines, and use thereof in immune-oncological applications |
| EP18199879.0 | 2018-10-11 | ||
| PCT/EP2019/077644 WO2020074724A1 (en) | 2018-10-11 | 2019-10-11 | Binding protein-toxin conjugates comprising anthracyclines, and use thereof in immune-oncological applications |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022512672A JP2022512672A (ja) | 2022-02-07 |
| JP2022512672A5 true JP2022512672A5 (cg-RX-API-DMAC7.html) | 2022-10-21 |
| JP7607556B2 JP7607556B2 (ja) | 2024-12-27 |
Family
ID=63833918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021519849A Active JP7607556B2 (ja) | 2018-10-11 | 2019-10-11 | アントラサイクリンを含む結合タンパク質-毒素融合体、および免疫腫瘍学的適用におけるその使用 |
Country Status (12)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024540099A (ja) | 2021-10-28 | 2024-10-31 | ライエル・イミュノファーマ・インコーポレイテッド | Ror1結合タンパク質を発現する細胞を培養する方法 |
| WO2023217227A1 (zh) | 2022-05-12 | 2023-11-16 | 先声再明医药有限公司 | 喜树碱类衍生物及配体-药物偶联物 |
| WO2024064952A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells overexpressing c-jun |
| WO2024064958A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2025217398A1 (en) | 2024-04-10 | 2025-10-16 | Lyell Immunopharma, Inc. | Methods for culturing cells with improved culture medium |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2777714A1 (en) | 2013-03-15 | 2014-09-17 | NBE-Therapeutics LLC | Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme |
| BR122020025870B1 (pt) | 2014-12-23 | 2024-01-09 | Nbe-Therapeutics Ag | Método para a produção de um conjugado de proteína de ligaçãofármaco |
| US20180028682A1 (en) | 2015-02-09 | 2018-02-01 | Nbe Therapeutics Ag | Maytansine-drug conjugates of her-2 specific binding proteins generated by site specific sortase-enzyme mediated conjugation |
| CA3001941A1 (en) | 2015-10-30 | 2017-05-04 | Nbe-Therapeutics Ag | Anti-ror1 antibodies |
| US20190112385A1 (en) | 2015-10-30 | 2019-04-18 | Nbe-Therapeutics Ag | Anti-mesothelin antibodies |
| MX2018008926A (es) * | 2016-01-20 | 2019-01-10 | Scripps Research Inst | Composiciones de anticuerpo contra ror1 y métodos relacionados. |
| CN109311982A (zh) * | 2016-01-20 | 2019-02-05 | 斯克利普斯研究所 | Ror2抗体组合物和相关方法 |
| PL3964529T3 (pl) * | 2016-01-22 | 2025-10-27 | MabQuest SA | Nieblokujące przeciwciała specyficzne względem pd1 |
| SG11201901624RA (en) * | 2016-09-07 | 2019-03-28 | Univ Canberra | Lysine specific histone demethylase-1 inhibitors and uses therefor |
| WO2018103739A1 (zh) * | 2016-12-09 | 2018-06-14 | 凯惠科技发展(上海)有限公司 | 抗体药物偶联物、制备方法、中间体、药物组合物及应用 |
| JP7359700B2 (ja) * | 2017-06-20 | 2023-10-11 | ソレント・セラピューティクス・インコーポレイテッド | Cd38抗体薬物コンジュゲート |
| US20210139579A1 (en) * | 2017-07-20 | 2021-05-13 | Nbe-Therapeutics Ag | Multispecific antibody product that binds to different ror1 epitopes |
| US11447546B2 (en) | 2017-07-20 | 2022-09-20 | Nbe-Therapeutics Ag | Human antibodies binding to ROR2 |
| KR20230008269A (ko) * | 2017-08-07 | 2023-01-13 | 엔비이-테라퓨틱스 아게 | 생체 내 내성이 높은 항체 약물 결합체 |
| GB201721802D0 (en) * | 2017-12-22 | 2018-02-07 | Almac Discovery Ltd | Ror1-specific antigen binding molecules |
-
2018
- 2018-10-11 EP EP18199879.0A patent/EP3636284A1/en not_active Withdrawn
-
2019
- 2019-10-11 AU AU2019358518A patent/AU2019358518A1/en not_active Abandoned
- 2019-10-11 US US17/283,924 patent/US20210379194A1/en not_active Abandoned
- 2019-10-11 CA CA3112848A patent/CA3112848A1/en active Pending
- 2019-10-11 EP EP19783544.0A patent/EP3863681A1/en active Pending
- 2019-10-11 WO PCT/EP2019/077644 patent/WO2020074724A1/en not_active Ceased
- 2019-10-11 MX MX2021003136A patent/MX2021003136A/es unknown
- 2019-10-11 EA EA202190653A patent/EA202190653A1/ru unknown
- 2019-10-11 BR BR112021006269-6A patent/BR112021006269A2/pt unknown
- 2019-10-11 KR KR1020217010212A patent/KR20210075085A/ko not_active Ceased
- 2019-10-11 CN CN201980066701.6A patent/CN112805037A/zh active Pending
- 2019-10-11 JP JP2021519849A patent/JP7607556B2/ja active Active
-
2021
- 2021-04-05 PH PH12021550750A patent/PH12021550750A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025163055A5 (cg-RX-API-DMAC7.html) | ||
| JP2022177090A5 (cg-RX-API-DMAC7.html) | ||
| JP2020063262A5 (cg-RX-API-DMAC7.html) | ||
| WO2021244089A1 (zh) | 新型冠状病毒(sars-cov-2)刺突蛋白结合分子及其应用 | |
| JP2022101693A5 (cg-RX-API-DMAC7.html) | ||
| JP2023549537A5 (cg-RX-API-DMAC7.html) | ||
| HRP20241417T1 (hr) | Bifunkcionalno antitijelo anti-pd-1 i anti-vegfa, njegov farmaceutski pripravak i njegova uporaba | |
| JP2019531084A5 (cg-RX-API-DMAC7.html) | ||
| JP2017531028A5 (cg-RX-API-DMAC7.html) | ||
| CN113412281B (zh) | Btn3a结合蛋白及其用途 | |
| JP2020534830A5 (cg-RX-API-DMAC7.html) | ||
| JP2023539501A5 (cg-RX-API-DMAC7.html) | ||
| JP2013527761A5 (cg-RX-API-DMAC7.html) | ||
| BR112020012464A2 (pt) | molécula de ligação ao antígeno biespecífica; proteína de fusão recombinante, receptor de antígeno quimérico, célula, sequência de ácidos nucleicos, vetor, célula hospedeira, método para preparar uma molécula de ligação ao antígeno biespecífica, proteína de fusão recombinante ou receptor de antígeno quimérico, composição farmacêutica, uso de uma molécula de ligação ao antígeno biespecífica, método para tratamento de uma doença em um paciente que necessita de tratamento, método para avaliar a presença de um analito-alvo em uma amostra, método para imageamento de um sítio de doença em um indivíduo, método para diagnóstico de uma doença ou afecção médica em um indivíduo, anticorpo, fragmento de anticorpo ou molécula de ligação ao antígeno, kit e método para diagnóstico de um indivíduo que sofre de câncer, ou uma predisposição para o mesmo, ou para fornecer um prognóstico da afecção de um indivíduo, método para eliminar ou inibir o crescimento de uma célula que expressa ror1 e egfr in vitro ou em um paciente | |
| JP2021508707A5 (cg-RX-API-DMAC7.html) | ||
| JP2020521478A5 (cg-RX-API-DMAC7.html) | ||
| JP2021513848A5 (cg-RX-API-DMAC7.html) | ||
| JP2020534012A5 (cg-RX-API-DMAC7.html) | ||
| FI3941946T3 (fi) | Klaudiini-6-vasta-aineita ja klaudiini-6-vasta-ainelääkekonjugaatteja | |
| JP2022553922A5 (cg-RX-API-DMAC7.html) | ||
| CN116940598A (zh) | 用于治疗表达cldn18.2的实体瘤的cldn18.2/cd3双特异性抗体 | |
| JP2005528914A5 (cg-RX-API-DMAC7.html) | ||
| JP2018528759A5 (cg-RX-API-DMAC7.html) | ||
| JP2024537323A5 (cg-RX-API-DMAC7.html) | ||
| JP2023542900A5 (cg-RX-API-DMAC7.html) |